| Drug | Contraindications | Warnings |
| Amphotericin B deoxycholate | Hypersensitivity to amphotericin B | Anaphylaxis |
| Lipid formulations of AMB | Hypersensitivity to amphotericin B | Anaphylaxis |
| Fluconazole | Hypersensitivity to fluconazole | Hepatic injury, anaphylaxis, and dermatologic |
| Itraconazole | Terfenadine, astemizole, dofetilide, pimozide, quinidine, oral midazolam, triazolam, cisapride, and statins should also be discontinued during therapy | Black box for terfenadine and congestive Heart failure see contraindications |
| Posaconazole | Hypersensitivity to the active substance or excipients, ergot alkaloids, coadministration with 3A4 substrates (terfenadine, astemizole, cisapride, pimozide, halofantrine, and quinidine) | Hypersensitivity, hepatic toxicity, recommended monitoring of hepatic function (LFTs), cyclosporine, tacrolimus, and sirolimus |
| Voriconazole | Hypersensitivity to voriconazole, CYP3A4 inhibitors (terfenadine, astemizole, cisapride, pimozide, and quinidine), sirolimus, rifampin, carbamezapine, long acting barbiturates, ritonavir, efavirenz, rifabutin, and ergot alkaloids (ergotamine and dihydroergotamine) | Visual disturbances, hepatic toxicity, recommended monitoring of LFTs and bilirubin, pregnancy category D, and galactose intolerance |
| Anidulafungin | Hypersensitivity to anidulafungin or other echinocandins | None |
| Caspofungin | Hypersensitivity to caspofungin or other echinocandins | Elevated liver enzymes with cyclosporine |
| Micafungin | Hypersensitivity to micafungin or other echinocandins | Hypersensitivity, hematological effects (hemolysis, hemolytic anemia, and hemoglobinuria), hepatic effects (abnormal LFTs, hepatic dysfunction, hepatitis, and hepatic failure), and renal effects (elevations of BUN and creatinine, renal dysfunction, and acute renal failure) |
|
|